samedan logo
 
 
 
spacer
home > ebr > spring 2004 > to partner or not to partner?
PUBLICATIONS
European Biopharmaceutical Review

To Partner or Not to Partner?

The industry developments of the last decade have changed the shape of the pharmaceutical and biotech industry. With the consolidation of the pharma industry in the last decade and the increasing size of companies, R&D productivity, at least in relative terms, seems to be insufficient to support the growth expected by shareholders. The underlying need for alliances on the part of 'big pharma' in order to fuel growth by ensuring access to new products, and optimising drug development and commercialisation, seems to go from strength to strength. This has driven over 7,000 alliances worldwide between pharma and biotech companies from 1996 to 2002. At the same time, the total value of alliances has seen an explosion in growth from US$7 billion in 1996 to US$18 billion in 2002 - an increase of more than 150 per cent as big companies compete for the same assets. Alliances have surged to the point that most pharmaceutical companies see each other as potential partners; a remarkably different view compared to doing business 10 to 15 years ago.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dimitri F Dimitriou MSc, is the CEO of DyoDelta Biosciences Ltd, a London-based company specialising in partnerships in the pharma and biotech industry. Dimitri has almost 20 years' experience of corporate transactions/business development, general management, marketing, sales, finance and R&D in the pharma and biotech sectors. Prior to founding DyoDelta Biosciences, he was Senior Director of Worldwide Business Development at GlaxoSmithKline. He left GSK in 2001 in order to move to the biotech sector as CEO of the London-based drug discovery company Xcellsyz, and in addition founded DyoDelta Biosciences. He received his first degree in Biochemistry from the University of London prior to graduating in Pathology and Toxicology from the Royal Postgraduate Medical School in London in 1984.
spacer
Dimitri F Dimitriou
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinsonís disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement